Authors
Mark B Loeb, D William Molloy, Marek Smieja, Tim Standish, Charles H Goldsmith, Jim Mahony, Stephanie Smith, Michael Borrie, Earl Decoteau, Warren Davidson, Allan Mcdougall, Judy Gnarpe, Martin O'donnell, Max Chernesky
Publication date
2004/3
Journal
Journal of the American Geriatrics Society
Volume
52
Issue
3
Pages
381-387
Publisher
Blackwell Science Inc
Description
Objectives: To assess whether doxycycline and rifampin have a therapeutic role in patients with Alzheimer's disease (AD).
Design: Randomized, triple‐blind, controlled trial.
Setting: Three tertiary care and two community geriatric clinics in Canada.
Participants: One hundred one patients with probable AD and mild to moderate dementia.
Intervention: Oral daily doses of doxycycline 200 mg and rifampin 300 mg for 3 months.
Measurements: The primary outcome was a change in Standardized Alzheimer's Disease Assessment Scale cognitive subscale (SADAScog) at 6 months. Secondary outcomes were changes in the SADAScog at 12 months and tests of dysfunctional behavior, depression, and functional status.
Results: There was significantly less decline in the SADAScog score at 6 months in the antibiotic group than in the placebo group, (−2.75 points, 95% confidence interval (CI)=−5.28 to −0.22, P=.034). At …
Total citations
Scholar articles
MB Loeb, DW Molloy, M Smieja, T Standish… - Journal of the American Geriatrics Society, 2004